Amgen (AMGN) Proxy filing summary

Executive summary

• Achieved 10% year-over-year revenue and sales growth in 2025, with 18 products reaching record sales and 14 exceeding $1 billion in sales.

• Advanced R&D with five FDA approvals and significant progress in obesity, oncology, rare disease, and inflammation therapeutic areas.

• Expanded U.S. manufacturing with $900 million investment in Ohio, $650 million in Puerto Rico, and broke ground on a $600 million innovation center in California.

• Provided $19 billion in medicines at no cost to eligible patients since 2001 and reached over 80 million students and teachers through science education programs.

Voting matters and shareholder proposals

• Board recommends voting for all 12 director nominees, for executive compensation, for ratification of Ernst & Young LLP as auditor, and against a proposal requiring an independent Board chair.

• Board highlights strong director qualifications, diversity, and refreshment, with 8 new directors since 2016 and an average tenure of ~8 years.

• Maintains a highly independent Board, with only independent directors on key committees and a lead independent director with significant responsibilities.

• Opposes the independent chair proposal, citing robust independent oversight, annual leadership evaluations, and strong recent performance under current structure.

Board of directors and corporate governance

• Board consists of leaders with experience in public companies, scientific research, healthcare, finance, and regulatory compliance.

• Board practices annual review of director commitments and maintains strict limits on outside board service.

• Engaged with stockholders representing 59% of outstanding shares since the last annual meeting, leading to enhanced disclosures and governance practices.